Pharma's Health Reform Deal: Kindler Departure Facilitates GOP Re-Alignment
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer exec was a key symbol of pharma's strategy to sign on early to the Obama health reform proposal.
You may also be interested in...
Pfizer Watchers Try To Read New CEO's Next Moves
Pfizer, Inc.,'s abrupt management shake-up, announced Dec. 5, comes almost a year to the day its key drug Lipitor goes off patent. Whether the timing of the changes was a coincidence or the result of accumulating pressures, the patent expiration date of November 2011 is a marker for new CEO Ian Read and portends additional changes at the world's largest drug manufacturer.
Pfizer Watchers Try To Read New CEO's Next Moves
Pfizer, Inc.,'s abrupt management shake-up, announced Dec. 5, comes almost a year to the day its key drug Lipitor goes off patent. Whether the timing of the changes was a coincidence or the result of accumulating pressures, the patent expiration date of November 2011 is a marker for new CEO Ian Read and portends additional changes at the world's largest drug manufacturer.
Merck's Frazier Promoted to CEO to Steer Merck To Post-Schering Success
In a widely anticipated move, Merck has named current president Ken Frazier as CEO